Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 8 for:    NAFCILLIN AND cloxacillin

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02208063
Recruitment Status : Terminated (Halted due to lack of statistical power. No safety concerns identified.)
First Posted : August 4, 2014
Results First Posted : February 17, 2020
Last Update Posted : February 17, 2020
Sponsor:
Information provided by (Responsible Party):
Cumberland Pharmaceuticals

Brief Summary:
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).

Condition or disease Intervention/treatment Phase
Bacteremia Drug: Telavancin Drug: Vancomycin Drug: Daptomycin Drug: Synthetic penicillin Drug: Cefazolin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis
Actual Study Start Date : December 2014
Actual Primary Completion Date : April 12, 2018
Actual Study Completion Date : April 12, 2018


Arm Intervention/treatment
Experimental: Telavancin
7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
Drug: Telavancin
Active Comparator: Standard of care
Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
Drug: Vancomycin
Drug: Daptomycin
Other Name: Cubicin

Drug: Synthetic penicillin
Other Names:
  • Nafcillin
  • Oxacillin
  • Cloxacillin

Drug: Cefazolin



Primary Outcome Measures :
  1. Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC) [ Time Frame: Up to 8 weeks ]

    The efficacy endpoint of clinical outcome of cure at the test of cure (TOC) was determined by subjects who meet all of the following criteria, as determined by the investigator and adjudicated by the blinded independent efficacy adjudication committee (IEAC).

    1. Alive at TOC
    2. Resolution of all clinical signed and symptoms of the Staphylococcus aureus (S. aureus) infection at TOC
    3. No evidence of microbiological persistence of relapse
    4. No new foci of metastatic S. aureus infection after Day 8


Secondary Outcome Measures :
  1. Number of Participants With an Investigator Clinical Outcome of Cure at TOC in the Microbiological All-treated (mAT) Population [ Time Frame: Up to 8 weeks ]

    The efficacy endpoint of Investigator clinical outcome of cure at the test of cure (TOC) was determined by the following criteria:

    1. Subject alive at TOC
    2. Resolution of all clinical signs and symptoms of the S. aureus infection at TOC (unless explained by a more likely alternative diagnosis)
    3. No evidence of microbiological persistence or relapse
    4. No new foci of metastatic S. aureus infection after Day 8

  2. Investigator Clinical Response (Success or Failure) at EOT in the Microbiological All-treated (mAT) Population [ Time Frame: Up to 8 weeks ]
    This efficacy endpoint was determined to be a clinical failure if the subject switched study antibiotic due to lack of clinical response

  3. Number of Participants With the Development of a New Metastatic Foci of S. Aureus Infection at Test of Cure (TOC) in the Microbiological All-treated (mAT) Populations [ Time Frame: Day 8 ]
    After Day 8, any sign or symptom leading to a subsequent confirmed diagnosis of a new metastatic foci of S. aureus infection



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older with at least one blood culture positive for S. aureus within 48 hours before randomization
  • At least one of the following signs or symptoms of bacteremia:

    • Temperature ≥ 38.0°C
    • White blood cell (WBC) count > 10,000 or < 4,000 cells/µL or > 10% immature neutrophils (bands)
    • Tachycardia (heart rate > 90 bpm)
    • Tachypnea (respiratory rate > 20 breaths/min)
    • Hypotension (systolic blood pressure < 90 mmHg)
    • Signs or symptoms of localized catheter-related infection
  • At enrollment, subjects must have either 1) known right-sided infective endocarditis by Modified Duke's criteria 2) known complicated bacteremia, demonstrated as signs or symptoms of metastatic foci of S. aureus infection or 3) at least one risk factor for complicated bacteremia.

Exclusion Criteria:

  • Treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 60 hours within 7 days before randomization. EXCEPTION: Documented resistance to the prior systemic antibacterial therapy
  • Presence of an infection source that will not be managed or controlled within the first 3 days of study drug treatment
  • Presence of prosthetic cardiac valve or cardiac device (eg, implantable cardioverter defibrillator [ICD]), permanent pacemaker, or cardiac valve support ring)
  • Known or suspected left-sided infective endocarditis (LIE), by Modified Duke Criteria. NOTE: Right-sided infective endocarditis (RIE) is permitted
  • Known or suspected osteomyelitis or meningitis. NOTE: Evidence of metastatic complications related to the primary infection such as right-sided endocarditis, septic arthritis, septic pulmonary emboli are permitted. S. aureus pneumonia is permitted
  • Confirmed evidence (identification or gram stain) of a mixed polymicrobial infection with a Gram-negative pathogen that requires non-study antibiotic treatment with agent(s) that have activity against Gram-negative pathogens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02208063


Locations
Layout table for location information
United States, Ohio
Remington-Davis Clinical Research
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Cumberland Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Medical Monitor Cumberland Pharmaceuticals, Inc.
  Study Documents (Full-Text)

Documents provided by Cumberland Pharmaceuticals:
Study Protocol  [PDF] January 16, 2018
Statistical Analysis Plan  [PDF] April 26, 2018


Layout table for additonal information
Responsible Party: Cumberland Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02208063    
Other Study ID Numbers: 0112
First Posted: August 4, 2014    Key Record Dates
Results First Posted: February 17, 2020
Last Update Posted: February 17, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Cumberland Pharmaceuticals:
Bacteremia
Staphylococcus aureus
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacteremia
Bacterial Infections
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Vancomycin
Cefazolin
Penicillins
Daptomycin
Telavancin
Anti-Bacterial Agents
Anti-Infective Agents